Browsing Pharmaceutical sciences by Title
Now showing items 21-40 of 76
-
Demographic, Geographic, and Clinical Characteristics Associated with Receipt of Influenza Outpatient Oral Antiviral Treatment in Commercially Insured US Patients: An Exploration of Potential Health Disparities
Background: Marginalized groups have been shown to experience a greater portion of the annual morbidity of influenza in the US. Identifying characteristics associated with receipt of outpatient oral antiviral treatment ... -
Dietary Therapy for Pediatric Inflammatory Bowel Disease: An Epidemiologic and Economic Analysis
The objective of this study was to assess the potential health outcomes and economic impact of the Specific Carbohydrate Diet (SCD) as a therapeutic option for pediatric patients with inflammatory bowel disease (IBD). In ... -
Direct Health Care Costs of Metastatic Ovarian Cancer in a Commercially-Insured Population: A Retrospective Database Analysis
Background: Ovarian cancer is the 10th most common type of cancer and the 5th leading cause of cancer death among women in the United States (U.S.). The majority of incident ovarian cancer cases are diagnosed in individual ... -
Does Cost-Effectiveness Analysis Have a Role in US Managed Care Drug Formularies? An Empirical Study of Utilization, Costs, Outcomes, and Elasticity of Demand of a Value-Based Formulary
The standard economic model for health insurance posits that in order to account for moral hazard in a population for which there is varying marginal benefit of treatment that is unknown to the insurer, cost-sharing should ... -
THE ECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN A WORKING AGE AND COMMERCIALLY INSURED POPULATION
(2013-07-25)INTRODUCTION: Diabetic Macular Edema (DME) is the leading cause of blindness amongst working age adults in most developed countries. Diagnosis and treatment of DME involves many visits to specialists, numerous medications, ... -
Estimating the inpatient and outpatient costs of atrial fibrillation and associated adverse events
(2013-07-25)<bold>ABSTRACT</bold> <bold>Background</bold> In the last several years three new anticoagulant options have come on to the market, altering the risk/benefit profile of stroke prevention therapy. The development of useful ... -
Evaluating Healthcare Resource Utilization and Associated Costs for Patients with New-onset Post-operative Atrial Fibrillation
BACKGROUND: New-onset post-operative atrial fibrillation (POAF) is one of the most common complications following cardiac surgery. Previous studies have found that patients with POAF experience longer hospital lengths of ... -
Evaluating Methods to Estimate United States Multiple Sclerosis Prevalence from Administrative Health Claims Data
Introduction The prevalence of Multiple Sclerosis (MS) in the United States (US) historically has been poorly described, in part because disease activity is intermittent, making detection using administrative health claims ... -
Evaluating Recent Policies to Accelerate Generic Drug Entry
Generic drugs can bring more competition to the market and help to reduce drug costs. Governmental pharmaceutical regulations operate to balance innovation, access, and cost. Encouraging more generic entries is one mechanism ... -
Evaluating the Clinical Utility of a New Risk Prediction Model in Cystic Fibrosis
Risk prediction models (RPMs), which estimate the probability of some future event, can inform clinical decisions about appropriate testing and treatment. Novel, machine learning (ML)-based RPMs have demonstrated superior ... -
Evaluating the Effect of Treatment Satisfaction on Future Spending for Professional Cosmetic Treatments Among Aesthetically Conscious U.S. Adults
BACKGROUND: Professional cosmetic treatments are increasing in popularity within the United States, amounting to billions of dollars in annual spending on a wide variety of surgical and nonsurgical treatments combined. ... -
Exploring the uptake of value-based formulary strategies and their application to specialty drugs
Background: Value-based formularies (VBF) are a way to implement the overarching idea of value-based insurance design (VBID) by tying pharmacy cost-sharing to value based on cost-effectiveness evidence. Empirical evidence ... -
Geographic Variation in the Use of Triptans and Opioids for the Acute Treatment of Migraine Attacks
BACKGROUND: Clinical guidelines and published literature suggest that opioids should be used sparingly or avoided in patients with acute migraine due to a lack of evidence of their effectiveness, association with disease ... -
Health and Economic Burden of Substandard and Falsified Medicines
One in 10 medical products in low- and middle-income countries (LMICs) are reportedly substandard or falsified (SF). Poor quality medicines burden health systems and individuals by diverting resources to harmful or ineffective ... -
Healthcare Resource Use and Costs Associated with Chronic Migraines vs. Non-migraine controls and Episodic Migraines vs. Non-migraine controls
BACKGROUND: Migraines are a debilitating neurological condition highly prevalent worldwide. Migraines can be characterized as chronic or episodic, depending on frequency and intensity. Chronic migraines are defined by the ... -
Healthcare resource utilization and costs among multiple myeloma patients with double- or triple-class exposure: a retrospective U.S. claims database analysis
Background: Despite recent advancements in the therapeutic landscape, MM remains incurable, and most patients require several lines of therapies (LOTs). The lack of treatment options for these patients has prompted the ... -
Healthcare Resource Utilization and Costs Associated with Misdiagnosis of Migraine
BACKGROUND: Migraine is commonly misdiagnosed and undertreated and can be confused with other conditions that also cause facial pain or headache. The most common misdiagnoses for migraine are headache, sinusitis, and ... -
Healthcare Resource Utilization and Costs Associated with Non-Adherence to Pharmacotherapy for Major Depressive Disorder
BACKGROUND: Major Depressive Disorder (MDD) affects more than 16 million adults in the United States (US) and accounted for $210 billion in direct and indirect costs in the US in 2010. Pharmacological treatments for MDD ... -
Healthcare Utilization and Costs associated with Sickle-cell disease in the United States: A Retrospective Claims Analysis
Introduction: Sickle cell disease (SCD) is a group of hereditary hematological disorders that are associated with high rate of medical resource utilization and medical costs. In the past few decades, improvement in medical ... -
Healthcare utilization and expenditures of parents with and without hemophilia A children
Background: There is a growing body of evidence characterizing the experience of caring for children with hemophilia A (HA), which includes negative impact on health-related quality of life, emotional stress, and financial ...